Organization type

  • Biotech

Early phases

  • Systems biology
  • Target identification – new biological hypothesis

Screening

  • Chemical libraries
    • Small molecules (including natural product, DNA encoded libraries and fragment libraries)
  • Fragment based screening
    • Hit expansion. Medicinal chemistry programs.
    • Virtual screening
  • Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)

Optimization phases

  • Mechanism of action (MoA) assessment
    • Selectivity panels
    • Target deconvolution
  • Medicinal chemistry programs for hit to lead and lead optimization
  • Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
    • ADME / DMPK
    • Safety
    • Toxicology

Functional areas

  • Artificial intelligence
  • Bioinformatics
  • Compound management
  • Structural biology

Terapeutic areas

  • Autoimmunity / Inflammation
  • Cancer
  • Cardiovascular
  • Infectious diseases
  • Nervous Central System
  • Rare diseases

Additional activities

  • Consulting services
  • CROs providing no-regulatory and regulatory services for drug discovery